AmMax Bio Inc.
AmMax Bio is a clinical stage oncology-focused biotech company. We are leveraging our expertise in translational science and drug development to build an innovative portfolio via partnering and collaboration. Core to its portfolio are AMB-066, an mAb in Phase 2a for treating CRC MRD, and AMB-104, an ADC, in preclinical phase for hematological and solid tumors.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}